Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO
Laura Shawver didn’t quite understand cancer until she had it.
By that point, in 2006, she had already been making oncology drugs for over 15 years, a dyed-in-the-wool researcher who had obtained a PhD in pharmacology before retraining herself as a molecular biologist in the heady pre-Dolly days of cloning. She knew all about tumors. She knew the genes that drove them and the drugs that halted them. Her previous company, Sugen, had sequenced cancers to develop sunitinib, one of the first kinase inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.